Literature DB >> 8035988

Visual outcomes of macular retinoblastoma after external beam radiation therapy.

A H Weiss1, D J Karr, R E Kalina, K L Lindsley, T W Pendergrass.   

Abstract

PURPOSE: To determine the risk factors that influence the visual outcomes of patients with macular retinoblastoma who are treated with radiation therapy.
METHODS: The medical records of all patients with macular retinoblastoma treated with radiation therapy between 1980 and 1990 were reviewed. Ten patients were entered into the study. Features analyzed included patient age, laterality of eye involvement, location and size of macular tumor(s) at the time of diagnosis, treatment course, and most recent visual acuity.
FINDINGS: Ten of 11 eyes (10 patients) were successfully treated with external beam radiation. Eight patients obtained visual acuities ranging from 20/25 to 20/100; two patients had visual acuities of 20/200 or less. The best visual acuities were noted in patients whose tumor(s) did not involve the fovea and were relatively small. The worse visual acuities were noted in patients with binocular vision whose tumors invaded the fovea and were larger in size. In two of three patients in whom both eyes were retained, superimposed amblyopia developed in the eye with macular retinoblastoma.
CONCLUSION: The authors' findings indicate that most patients with macular retinoblastoma who are treated with external beam radiation have favorable visual outcomes, but final visual acuity depends on the size of the tumor and involvement of the fovea. Patients in whom both eyes are retained are predisposed to further visual loss from amblyopia.

Entities:  

Mesh:

Year:  1994        PMID: 8035988     DOI: 10.1016/s0161-6420(94)31182-1

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  6 in total

1.  Long-term visual outcomes in intraocular retinoblastoma with eye preservation.

Authors:  A Batra; N Pushker; P Venkatesh; T Arora; R Tewari; S Bakhshi
Journal:  Clin Transl Oncol       Date:  2016-01-19       Impact factor: 3.405

2.  Systemic neoadjuvant chemotherapy for Group B intraocular retinoblastoma (ARET0331): A report from the Children's Oncology Group.

Authors:  Debra L Friedman; Mark Krailo; Doojduen Villaluna; Dan Gombos; Bryan Langholz; Rima Jubran; Carol Shields; Linn Murphree; Joan O'Brien; Sandra Kessel; Carlos Rodriguez-Galindo; Murali Chintagumpala; Anna T Meadows
Journal:  Pediatr Blood Cancer       Date:  2016-12-26       Impact factor: 3.167

Review 3.  Retinoblastoma and vision.

Authors:  Omar Warda; Zishan Naeem; Kelsey A Roelofs; Mandeep S Sagoo; M Ashwin Reddy
Journal:  Eye (Lond)       Date:  2022-01-05       Impact factor: 3.775

4.  Role of chemotherapy alone or in combination with hyperthermia in the primary treatment of intraocular retinoblastoma: preliminary results.

Authors:  C Levy; F Doz; E Quintana; H Pacquement; J Michon; P Schlienger; P Validire; B Asselain; L Desjardins; J M Zucker
Journal:  Br J Ophthalmol       Date:  1998-10       Impact factor: 4.638

5.  Visual prognosis of retinoblastoma in the posterior pole treated with primary chemotherapy plus local treatments.

Authors:  Jae Min Kim; Jeong Hun Kim; Seong-Joon Kim; Kyung Duk Park; Hee Young Shin; Hyo Seop Ahn; Young Suk Yu
Journal:  Korean J Ophthalmol       Date:  2010-11-23

6.  Swept-source optical coherence tomography features of regressed macular retinoblastoma.

Authors:  Sourav Damodaran; Mandeep S Bajaj; Pradeep Sharma; Atul Kumar; Rohan Chawla; Amar Pujari; Gaurav Garg; Shreyas Temkar
Journal:  Indian J Ophthalmol       Date:  2019-12       Impact factor: 1.848

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.